




Belgian Cancer Registry

CANCER FACT SHEET 2022

OESOPAGHEAL CANCER

ICD-10 C15-C16.0



CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative change in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later ($=200 \times 1.05$) and 255/100,000 over 5 years ($=200 \times (1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

ADC: Adenocarcinomas

SCC: Squamous cell carcinomas



1. CANCER INCIDENCE	5
1.1. Oesopagheal cancer incidence: by region	5
1.1.1. Oesopagheal cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022	5
1.2. Oesopagheal cancer incidence: by tumour stage	7
1.2.1. Oesopagheal cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022	7
1.2.2. Oesopagheal cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022	7
1.2.3. Oesopagheal cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022	8
1.3. Oesopagheal cancer incidence: by tumour type	9
1.3.1. Oesopagheal cancer incidence by type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022	9
1.4. Oesopagheal cancer incidence: by tumour sub-location	9
1.4.1. Oesopagheal cancer incidence by sub-location, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022	9
1.5. Oesopagheal cancer incidence: by tumour type and tumour stage	10
1.5.1. Oesopagheal cancer incidence by type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022	10
1.6. Oesopagheal cancer incidence: by tumour sub-location and tumour stage	11
1.6.1. Oesopagheal cancer incidence by sub-location, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022	11
1.7. Oesopagheal cancer incidence: by tumour sub-location and tumour type	13
1.7.1. Oesopagheal cancer incidence by sub-location, type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022	13
2. CANCER INCIDENCE TRENDS	14
2.1. Oesopagheal cancer incidence trends: by region	14
2.1.1. Oesopagheal cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022	14
2.1.2. Oesopagheal cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022	15
2.2. Oesopagheal cancer incidence trends: by tumour stage	16
2.2.1. Oesopagheal cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards ...	16
2.3. Oesopagheal cancer incidence trends: by tumour type	18
2.3.1. Oesopagheal cancer incidence trends by type and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards ...	18
2.4. Oesopagheal cancer incidence trends: by tumour sub-location	19
2.4.1. Oesopagheal cancer incidence trends by sub-location and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards ...	19

2.5. Oesopagheal cancer incidence trends: by age group.....	21
2.5.1. Oesopagheal cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	21
2.5.2. Oesopagheal cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	22
3. CANCER PREVALENCE.....	23
3.1. Oesopagheal cancer prevalence: by region.....	23
3.1.1. Oesopagheal cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022	23
4. CANCER SURVIVAL.....	24
4.1. Oesopagheal cancer survival: by region	24
4.1.1. Oesopagheal cancer survival by region, sex and age group: number at risk and net survival probabilities, 2013-2022.....	24
4.2. Oesopagheal cancer survival: by tumour stage	26
4.2.1. Oesopagheal cancer survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2013-2022	26
4.2.2. Oesopagheal cancer survival by pathological stage (pStage), and sex: number at risk and net survival probabilities, 2013-2022	27
4.2.3. Oesopagheal cancer survival by stage and sex: number at risk and net survival probabilities, 2013-2022.....	28
4.3. Oesopagheal cancer survival: by tumour type and tumour stage	29
4.3.1. Oesopagheal cancer survival by type, stage and sex: number at risk and net survival probabilities, 2013-2022	29
5. CANCER SURVIVAL TRENDS.....	32
5.1. Oesopagheal cancer survival trends: by tumour stage.....	32
5.1.1. Oesopagheal cancer survival trends by stage and sex: number at risk and net survival probabilities, 2008-2022	32
5.2. Oesopagheal cancer survival trends: by tumour type and tumour stage.....	34
5.2.1. Oesopagheal cancer survival trends by type, stage and sex: number at risk and net survival probabilities, 2008-2022.....	34
6. CANCER MORTALITY	37
6.1. Oesopagheal cancer mortality: by region.....	37
6.1.1. Oesopagheal cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021	37
7. CANCER MORTALITY TRENDS.....	39
7.1. Oesopagheal cancer mortality trends: by region	39
7.1.1. Oesopagheal cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021	39
7.1.2. Oesopagheal cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021	40

1. CANCER INCIDENCE



1.1. Oesophageal cancer incidence: by region

1.1.1. *Oesophageal cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022*

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Males																						
Belgium	0	0	0	0	0	1	2	11	9	24	47	100	155	212	213	181	113	64	18	2	1,152	21.4
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.5]	[3.0]	[2.4]	[6.4]	[11.9]	[24.8]	[42.0]	[67.9]	[80.7]	[95.1]	[89.3]	[81.6]	[59.9]	[34.2]	[20.2]	(20.2; 22.6)
Brussels	0	0	0	0	0	1	0	1	1	6	5	5	8	12	8	14	5	3	1	0	70	17.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.0]	[0.0]	[2.1]	[2.2]	[13.8]	[12.4]	[14.4]	[28.6]	[56.7]	[48.4]	[115.0]	[61.9]	[59.0]	[46.1]	[0.0]	[11.7]	(13.5; 22.2)
Flanders	0	0	0	0	0	0	1	7	4	12	25	61	91	132	136	122	80	46	11	1	729	21.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[3.3]	[1.8]	[5.7]	[10.8]	[25.0]	[40.5]	[68.7]	[84.1]	[98.8]	[95.7]	[87.7]	[55.2]	[26.5]	[22.0]	(20.2; 23.3)
Wallonia	0	0	0	0	0	0	1	3	4	6	17	34	56	68	69	45	28	15	6	1	353	21.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[2.6]	[3.5]	[5.0]	[13.7]	[27.2]	[48.2]	[68.5]	[80.4]	[82.4]	[80.1]	[71.8]	[75.7]	[65.0]	[19.7]	(19.1; 23.6)
Females																						
Belgium	0	0	0	0	1	0	0	0	4	9	20	30	49	74	64	62	53	47	19	4	436	6.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.0]	[0.0]	[0.0]	[1.1]	[2.5]	[5.2]	[7.5]	[13.0]	[22.2]	[21.7]	[26.8]	[29.7]	[34.9]	[27.4]	[19.5]	[7.4]	(6.2; 7.4)
Brussels	0	0	0	0	0	0	0	0	0	2	2	5	3	7	5	3	6	2	1	0	36	7.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[5.0]	[5.4]	[14.8]	[10.1]	[28.1]	[23.4]	[17.4]	[46.1]	[19.9]	[17.3]	[0.0]	[5.8]	(4.9; 9.7)

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Flanders	0	0	0	0	0	0	0	0	2	3	11	16	25	31	33	42	29	32	14	2	240	6.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[1.5]	[4.9]	[6.7]	[11.1]	[15.7]	[19.0]	[29.4]	[25.9]	[37.6]	[32.9]	[16.6]	[7.1]	(5.3; 6.9)
Wallonia	0	0	0	0	1	0	0	0	2	4	7	9	21	36	26	17	18	13	4	2	160	7.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.0]	[0.0]	[0.0]	[1.7]	[3.3]	[5.6]	[7.1]	[17.2]	[32.7]	[25.9]	[24.0]	[33.8]	[32.9]	[19.0]	[31.4]	[8.6]	(6.7; 9.1)

1.2. Oesophageal cancer incidence: by tumour stage

1.2.1. Oesophageal cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

cStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	18 [0.5]	66 [7.0]	42 [9.7]	126 [2.2]	2.3 (1.9; 2.7)	4 [0.1]	22 [2.2]	17 [2.7]	43 [0.7]	0.7 (0.5; 0.9)
II	12 [0.4]	60 [6.3]	43 [10.0]	115 [2.0]	2.1 (1.7; 2.5)	12 [0.4]	27 [2.7]	22 [3.5]	61 [1.0]	1.0 (0.7; 1.2)
III	49 [1.5]	154 [16.3]	103 [23.9]	306 [5.4]	5.7 (5.1; 6.4)	10 [0.3]	45 [4.5]	40 [6.3]	95 [1.6]	1.5 (1.2; 1.8)
IV	82 [2.4]	227 [24.0]	130 [30.2]	439 [7.7]	8.1 (7.3; 8.9)	23 [0.7]	59 [5.9]	50 [7.9]	132 [2.2]	2.1 (1.7; 2.4)
X/NA	33 [1.0]	73 [7.7]	60 [13.9]	166 [2.9]	3.1 (2.6; 3.6)	15 [0.5]	34 [3.4]	56 [8.8]	105 [1.8]	1.6 (1.2; 1.9)

1.2.2. Oesophageal cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

pStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	33 [1.0]	85 [9.0]	52 [12.1]	170 [3.0]	3.1 (2.6; 3.6)	3 [0.1]	30 [3.0]	13 [2.1]	46 [0.8]	0.7 (0.5; 0.9)
II	23 [0.7]	59 [6.2]	15 [3.5]	97 [1.7]	1.8 (1.4; 2.1)	3 [0.1]	14 [1.4]	7 [1.1]	24 [0.4]	0.4 (0.2; 0.5)
III	17 [0.5]	50 [5.3]	10 [2.3]	77 [1.3]	1.4 (1.1; 1.7)	6 [0.2]	12 [1.2]	6 [0.9]	24 [0.4]	0.4 (0.2; 0.6)
IV	18 [0.5]	41 [4.3]	19 [4.4]	78 [1.4]	1.4 (1.1; 1.7)	4 [0.1]	8 [0.8]	5 [0.8]	17 [0.3]	0.3 (0.1; 0.4)
X/NA	103 [3.1]	345 [36.5]	282 [65.4]	730 [12.8]	13.7 (12.7; 14.7)	48 [1.5]	123 [12.2]	154 [24.3]	325 [5.5]	5.0 (4.5; 5.6)

1.2.3. Oesophageal cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Stage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	30 [0.9]	82 [8.7]	59 [13.7]	171 [3.0]	3.2 (2.7; 3.6)	5 [0.2]	33 [3.3]	23 [3.6]	61 [1.0]	1.0 (0.7; 1.2)
II	11 [0.3]	54 [5.7]	38 [8.8]	103 [1.8]	1.9 (1.5; 2.3)	11 [0.3]	28 [2.8]	26 [4.1]	65 [1.1]	1.0 (0.8; 1.3)
III	49 [1.5]	158 [16.7]	99 [23.0]	306 [5.4]	5.7 (5.1; 6.3)	11 [0.3]	46 [4.6]	36 [5.7]	93 [1.6]	1.5 (1.2; 1.8)
IV	83 [2.5]	229 [24.2]	132 [30.6]	444 [7.8]	8.2 (7.4; 9.0)	23 [0.7]	59 [5.9]	50 [7.9]	132 [2.2]	2.1 (1.7; 2.4)
X/NA	21 [0.6]	57 [6.0]	50 [11.6]	128 [2.2]	2.4 (2.0; 2.8)	14 [0.4]	21 [2.1]	50 [7.9]	85 [1.4]	1.2 (1.0; 1.5)

1.3. Oesopagheal cancer incidence: by tumour type

1.3.1. Oesopagheal cancer incidence by type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Type	Males					Females				
	N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)		
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
ADC	135 [4.0]	368 [38.9]	269 [62.4]	772 [13.5]	14.4 (13.4; 15.4)	22 [0.7]	71 [7.1]	87 [13.7]	180 [3.1]	2.7 (2.3; 3.1)
SCC	45 [1.3]	176 [18.6]	85 [19.7]	306 [5.4]	5.6 (5.0; 6.3)	31 [0.9]	103 [10.3]	78 [12.3]	212 [3.6]	3.4 (2.9; 3.8)
Other and unspecified	14 [0.4]	36 [3.8]	24 [5.6]	74 [1.3]	1.4 (1.1; 1.7)	11 [0.3]	13 [1.3]	20 [3.2]	44 [0.7]	0.7 (0.5; 0.9)

1.4. Oesopagheal cancer incidence: by tumour sub-location

1.4.1. Oesopagheal cancer incidence by sub-location, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Sub-location	Males					Females				
	N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)		
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
Cervical	16 [0.5]	41 [4.3]	25 [5.8]	82 [1.4]	1.5 (1.2; 1.8)	12 [0.4]	35 [3.5]	23 [3.6]	70 [1.2]	1.1 (0.9; 1.4)
Thoracic	12 [0.4]	83 [8.8]	31 [7.2]	126 [2.2]	2.3 (1.9; 2.7)	11 [0.3]	44 [4.4]	38 [6.0]	93 [1.6]	1.5 (1.2; 1.8)
Abdominal	151 [4.5]	416 [44.0]	293 [68.0]	860 [15.1]	16.0 (14.9; 17.1)	32 [1.0]	92 [9.2]	105 [16.6]	229 [3.9]	3.5 (3.1; 4.0)
Unspecified	15 [0.4]	40 [4.2]	29 [6.7]	84 [1.5]	1.6 (1.2; 1.9)	9 [0.3]	16 [1.6]	19 [3.0]	44 [0.7]	0.7 (0.5; 0.9)

Note: The sub-location 'Abdominal' includes cardia (C16.0).

1.5. Oesophageal cancer incidence: by tumour type and tumour stage

1.5.1. Oesophageal cancer incidence by type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Type	Stage	Males					Females				
		N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)		
		15-59	60-74	75+	All ages	15-59	60-74	75+	All ages		
ADC	I	21 [0.6]	56 [5.9]	46 [10.7]	123 [2.2]	2.3 (1.9; 2.7)	1 [0.0]	14 [1.4]	8 [1.3]	23 [0.4]	0.4 (0.2; 0.5)
	II	5 [0.1]	19 [2.0]	17 [3.9]	41 [0.7]	0.8 (0.5; 1.0)	0 [0.0]	8 [0.8]	8 [1.3]	16 [0.3]	0.2 (0.1; 0.4)
	III	36 [1.1]	110 [11.6]	75 [17.4]	221 [3.9]	4.1 (3.6; 4.7)	4 [0.1]	19 [1.9]	24 [3.8]	47 [0.8]	0.7 (0.5; 0.9)
	IV	67 [2.0]	169 [17.9]	111 [25.7]	347 [6.1]	6.4 (5.8; 7.1)	15 [0.5]	27 [2.7]	28 [4.4]	70 [1.2]	1.1 (0.8; 1.4)
	X/NA	6 [0.2]	14 [1.5]	20 [4.6]	40 [0.7]	0.8 (0.5; 1.0)	2 [0.1]	3 [0.3]	19 [3.0]	24 [0.4]	0.3 (0.2; 0.4)
SCC	I	8 [0.2]	26 [2.7]	12 [2.8]	46 [0.8]	0.8 (0.6; 1.1)	4 [0.1]	18 [1.8]	15 [2.4]	37 [0.6]	0.6 (0.4; 0.8)
	II	6 [0.2]	35 [3.7]	21 [4.9]	62 [1.1]	1.2 (0.9; 1.4)	11 [0.3]	20 [2.0]	18 [2.8]	49 [0.8]	0.8 (0.6; 1.0)
	III	13 [0.4]	47 [5.0]	22 [5.1]	82 [1.4]	1.5 (1.2; 1.8)	7 [0.2]	27 [2.7]	12 [1.9]	46 [0.8]	0.8 (0.5; 1.0)
	IV	15 [0.4]	56 [5.9]	21 [4.9]	92 [1.6]	1.7 (1.3; 2.0)	7 [0.2]	31 [3.1]	20 [3.2]	58 [1.0]	0.9 (0.7; 1.1)
	X/NA	3 [0.1]	12 [1.3]	9 [2.1]	24 [0.4]	0.4 (0.3; 0.6)	2 [0.1]	7 [0.7]	13 [2.1]	22 [0.4]	0.3 (0.2; 0.5)
Other and unspecified	I	1 [0.0]	0 [0.0]	1 [0.2]	2 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	1 [0.1]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.1)
	II	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	III	0 [0.0]	1 [0.1]	2 [0.5]	3 [0.1]	0.1 (0.0; 0.1)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	IV	1 [0.0]	4 [0.4]	0 [0.0]	5 [0.1]	0.1 (0.0; 0.2)	1 [0.0]	1 [0.1]	2 [0.3]	4 [0.1]	0.1 (0.0; 0.1)
	X/NA	12 [0.4]	31 [3.3]	21 [4.9]	64 [1.1]	1.2 (0.9; 1.5)	10 [0.3]	11 [1.1]	18 [2.8]	39 [0.7]	0.6 (0.4; 0.8)

1.6. Oesophageal cancer incidence: by tumour sub-location and tumour stage

1.6.1. Oesophageal cancer incidence by sub-location, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Sub-location	Stage	Males					Females				
		N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)		
		15-59	60-74	75+	All ages	15-59	60-74	75+	All ages		
Cervical	I	1 [0.0]	6 [0.6]	2 [0.5]	9 [0.2]	0.2 (0.1; 0.3)	1 [0.0]	8 [0.8]	4 [0.6]	13 [0.2]	0.2 (0.1; 0.3)
	II	3 [0.1]	8 [0.8]	6 [1.4]	17 [0.3]	0.3 (0.2; 0.5)	6 [0.2]	5 [0.5]	4 [0.6]	15 [0.3]	0.2 (0.1; 0.4)
	III	4 [0.1]	8 [0.8]	6 [1.4]	18 [0.3]	0.3 (0.2; 0.5)	1 [0.0]	7 [0.7]	5 [0.8]	13 [0.2]	0.2 (0.1; 0.3)
	IV	6 [0.2]	13 [1.4]	5 [1.2]	24 [0.4]	0.4 (0.3; 0.6)	3 [0.1]	10 [1.0]	3 [0.5]	16 [0.3]	0.3 (0.1; 0.4)
	X/NA	2 [0.1]	6 [0.6]	6 [1.4]	14 [0.2]	0.3 (0.1; 0.4)	1 [0.0]	5 [0.5]	7 [1.1]	13 [0.2]	0.2 (0.1; 0.3)
Thoracic	I	5 [0.1]	16 [1.7]	5 [1.2]	26 [0.5]	0.5 (0.3; 0.6)	1 [0.0]	6 [0.6]	9 [1.4]	16 [0.3]	0.2 (0.1; 0.4)
	II	1 [0.0]	15 [1.6]	6 [1.4]	22 [0.4]	0.4 (0.2; 0.6)	3 [0.1]	6 [0.6]	11 [1.7]	20 [0.3]	0.3 (0.2; 0.4)
	III	1 [0.0]	21 [2.2]	9 [2.1]	31 [0.5]	0.6 (0.4; 0.8)	2 [0.1]	14 [1.4]	6 [0.9]	22 [0.4]	0.4 (0.2; 0.5)
	IV	5 [0.1]	27 [2.9]	7 [1.6]	39 [0.7]	0.7 (0.5; 0.9)	4 [0.1]	14 [1.4]	5 [0.8]	23 [0.4]	0.4 (0.2; 0.5)
	X/NA	0 [0.0]	4 [0.4]	4 [0.9]	8 [0.1]	0.1 (0.0; 0.3)	1 [0.0]	4 [0.4]	7 [1.1]	12 [0.2]	0.2 (0.1; 0.3)
Abdominal	I	22 [0.7]	56 [5.9]	49 [11.4]	127 [2.2]	2.4 (2.0; 2.8)	2 [0.1]	16 [1.6]	9 [1.4]	27 [0.5]	0.4 (0.3; 0.6)
	II	7 [0.2]	29 [3.1]	26 [6.0]	62 [1.1]	1.2 (0.9; 1.5)	2 [0.1]	13 [1.3]	9 [1.4]	24 [0.4]	0.4 (0.2; 0.5)
	III	42 [1.3]	122 [12.9]	75 [17.4]	239 [4.2]	4.4 (3.9; 5.0)	6 [0.2]	23 [2.3]	22 [3.5]	51 [0.9]	0.8 (0.6; 1.0)
	IV	69 [2.1]	169 [17.9]	111 [25.7]	349 [6.1]	6.5 (5.8; 7.2)	12 [0.4]	29 [2.9]	37 [5.8]	78 [1.3]	1.2 (0.9; 1.5)
	X/NA	11 [0.3]	40 [4.2]	32 [7.4]	83 [1.5]	1.6 (1.2; 1.9)	10 [0.3]	11 [1.1]	28 [4.4]	49 [0.8]	0.7 (0.5; 0.9)
Unspecified	I	2 [0.1]	4 [0.4]	3 [0.7]	9 [0.2]	0.2 (0.1; 0.3)	1 [0.0]	3 [0.3]	1 [0.2]	5 [0.1]	0.1 (0.0; 0.2)
	II	0 [0.0]	2 [0.2]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	4 [0.4]	2 [0.3]	6 [0.1]	0.1 (0.0; 0.2)
	III	2 [0.1]	7 [0.7]	9 [2.1]	18 [0.3]	0.4 (0.2; 0.5)	2 [0.1]	2 [0.2]	3 [0.5]	7 [0.1]	0.1 (0.0; 0.2)
	IV	3 [0.1]	20 [2.1]	9 [2.1]	32 [0.6]	0.6 (0.4; 0.8)	4 [0.1]	6 [0.6]	5 [0.8]	15 [0.3]	0.2 (0.1; 0.3)

Sub-location	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
X/NA		8 [0.2]	7 [0.7]	8 [1.9]	23 [0.4]	0.4 (0.2; 0.6)	2 [0.1]	1 [0.1]	8 [1.3]	11 [0.2]	0.2 (0.1; 0.3)

Note: The sub-location 'Abdominal' includes cardia (C16.0).

1.7. Oesopagheal cancer incidence: by tumour sub-location and tumour type

1.7.1. *Oesopagheal cancer incidence by sub-location, type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022*

Sub-location	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
Cervical	ADC	1 [0.0]	1 [0.1]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)	1 [0.0]	0 [0.0]	1 [0.2]	2 [0.0]	0.0 (0.0; 0.1)
	SCC	14 [0.4]	36 [3.8]	22 [5.1]	72 [1.3]	1.3 (1.0; 1.6)	11 [0.3]	35 [3.5]	19 [3.0]	65 [1.1]	1.0 (0.8; 1.3)
	Other and unspecified	1 [0.0]	4 [0.4]	3 [0.7]	8 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	0 [0.0]	3 [0.5]	3 [0.1]	0.0 (0.0; 0.1)
Thoracic	ADC	0 [0.0]	11 [1.2]	3 [0.7]	14 [0.2]	0.3 (0.1; 0.4)	1 [0.0]	7 [0.7]	6 [0.9]	14 [0.2]	0.2 (0.1; 0.3)
	SCC	12 [0.4]	70 [7.4]	26 [6.0]	108 [1.9]	2.0 (1.6; 2.3)	9 [0.3]	37 [3.7]	30 [4.7]	76 [1.3]	1.2 (0.9; 1.5)
	Other and unspecified	0 [0.0]	2 [0.2]	2 [0.5]	4 [0.1]	0.1 (0.0; 0.1)	1 [0.0]	0 [0.0]	2 [0.3]	3 [0.1]	0.0 (0.0; 0.1)
Abdominal	ADC	124 [3.7]	342 [36.2]	251 [58.2]	717 [12.6]	13.4 (12.4; 14.3)	18 [0.5]	61 [6.1]	76 [12.0]	155 [2.6]	2.4 (2.0; 2.7)
	SCC	15 [0.4]	45 [4.8]	24 [5.6]	84 [1.5]	1.6 (1.2; 1.9)	6 [0.2]	19 [1.9]	17 [2.7]	42 [0.7]	0.7 (0.5; 0.9)
	Other and unspecified	12 [0.4]	29 [3.1]	18 [4.2]	59 [1.0]	1.1 (0.8; 1.4)	8 [0.2]	12 [1.2]	12 [1.9]	32 [0.5]	0.5 (0.3; 0.7)
Unspecified	ADC	10 [0.3]	14 [1.5]	15 [3.5]	39 [0.7]	0.7 (0.5; 1.0)	2 [0.1]	3 [0.3]	4 [0.6]	9 [0.2]	0.1 (0.0; 0.2)
	SCC	4 [0.1]	25 [2.6]	13 [3.0]	42 [0.7]	0.8 (0.5; 1.0)	5 [0.2]	12 [1.2]	12 [1.9]	29 [0.5]	0.5 (0.3; 0.6)
	Other and unspecified	1 [0.0]	1 [0.1]	1 [0.2]	3 [0.1]	0.1 (0.0; 0.1)	2 [0.1]	1 [0.1]	3 [0.5]	6 [0.1]	0.1 (0.0; 0.2)

Note: The sub-location 'Abdominal' includes cardia (C16.0).

2. CANCER INCIDENCE TRENDS



2.1. Oesophageal cancer incidence trends: by region

2.1.1. *Oesophageal cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022*

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period		
Belgium	N	850	894	937	975	916	990	987	1,089	1,051	1,072	1,070	1,099	1,117	1,161	1,236	1,216	1,173	1,204	1,152			
	CR	16.7	17.5	18.2	18.8	17.5	18.8	18.6	20.3	19.4	19.7	19.5	20.0	20.2	20.9	22.1	21.6	20.7	21.2	20.2			
	ESR2013		20.5	21.1	22.1	22.2	20.8	22.3	21.9	24.0	22.3	22.6	22.3	22.4	22.4	23.3	24.2	23.4	22.4	22.8	21.4	0.2 (-0.2; 0.5)	2004-2022
																						0.7 (0.1; 1.3)	2004-2014
																					1.1 (-0.3; 2.6)	2015-2018	
																						-2.1 (-3.9; -0.3)	2019-2022
Brussels	N	66	57	67	70	62	77	65	74	79	78	87	58	60	84	67	68	66	68	70			
	CR	13.7	11.8	13.7	14.1	12.3	14.9	12.3	13.6	14.3	13.9	15.4	10.1	10.3	14.4	11.4	11.5	11.0	11.4	11.7			
	ESR2013	20.8	17.0	19.6	19.9	18.1	22.8	18.7	22.1	21.0	22.4	24.5	16.0	16.8	22.9	17.8	17.9	17.0	18.3	17.8	-0.6 (-1.7; 0.5)	2004-2022	
Flanders	N	498	521	555	597	553	605	595	614	618	651	659	667	707	680	763	746	757	767	729			
	CR	16.8	17.5	18.5	19.8	18.2	19.7	19.3	19.7	19.7	20.7	20.8	21.0	22.1	21.1	23.5	22.9	23.1	23.3	22.0			
	ESR2013	19.8	20.5	21.6	22.3	20.6	22.5	21.6	21.9	21.6	22.5	22.3	22.0	22.9	22.1	24.3	23.3	23.3	23.4	21.7	0.6 (0.3; 1.0)	2004-2022	
Wallonia	N	286	316	315	308	301	308	327	401	354	343	324	374	350	397	406	402	350	369	353			
	CR	17.4	19.2	19.0	18.5	17.9	18.2	19.2	23.4	20.5	19.8	18.6	21.4	19.9	22.5	22.9	22.6	19.6	20.7	19.7			
	ESR2013	21.4	23.2	24.0	22.5	21.9	21.5	22.9	28.4	24.0	22.9	21.5	24.5	22.8	25.6	25.4	25.0	21.9	22.7	21.3	0.1 (-0.5; 0.8)	2004-2022	

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Oesophageal cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period		
Belgium	N	293	310	277	312	292	305	324	348	359	372	388	377	396	369	405	392	390	390	436			
	CR	5.5	5.8	5.2	5.8	5.4	5.6	5.9	6.2	6.4	6.6	6.8	6.6	6.9	6.4	7.0	6.8	6.7	6.7	7.4			
	ESR2013	5.6	5.9	5.2	5.8	5.4	5.5	5.8	6.1	6.2	6.4	6.6	6.3	6.6	6.1	6.6	6.4	6.2	6.2	6.8	1.0 (0.5; 1.4)	2004-2022	
																					1.4 (0.8; 2.1)	2004-2016	
																						0.0 (-1.5; 1.4)	2017-2022
Brussels	N	30	27	20	36	39	24	29	30	34	30	26	27	32	29	30	22	28	17	36			
	CR	5.8	5.2	3.8	6.7	7.2	4.3	5.2	5.2	5.8	5.1	4.4	4.5	5.3	4.8	4.9	3.6	4.5	2.7	5.8			
	ESR2013	7.0	5.9	4.3	7.6	7.8	4.4	6.2	5.8	6.5	6.0	5.7	5.5	6.7	5.6	5.9	4.3	5.8	3.5	7.3	-0.9 (-2.8; 0.9)	2004-2022	
Flanders	N	156	178	166	166	149	182	174	215	198	210	213	225	225	208	239	234	235	247	240			
	CR	5.1	5.8	5.4	5.4	4.8	5.8	5.5	6.7	6.2	6.5	6.6	6.9	6.9	6.3	7.2	7.0	7.0	7.4	7.1			
	ESR2013	5.1	5.8	5.3	5.2	4.6	5.6	5.2	6.4	5.7	6.1	6.0	6.3	6.2	5.7	6.5	6.3	6.2	6.5	6.1	1.2 (0.6; 1.9)	2004-2022	
Wallonia	N	107	105	91	110	104	99	121	103	127	132	149	125	139	132	136	136	127	126	160			
	CR	6.1	6.0	5.2	6.2	5.8	5.5	6.7	5.7	7.0	7.2	8.1	6.8	7.5	7.1	7.3	7.3	6.8	6.8	8.6			
	ESR2013	6.3	6.1	5.3	6.3	6.1	5.6	6.9	5.6	7.0	7.2	7.9	6.5	7.2	7.0	7.0	6.9	6.4	6.3	7.9	1.1 (0.3; 2.0)	2004-2022	

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Oesophageal cancer incidence trends: by tumour stage

2.2.1. Oesophageal cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards

Stage	Males							Females							
	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
I	N	171	163	155	156	171			64	46	53	45	61		
	CR	3.1	2.9	2.7	2.7	3.0			1.1	0.8	0.9	0.8	1.0		
	ESR2013	3.3	3.1	2.9	3.0	3.2	1.2 (0.6; 1.8)	2004-2022	1.1	0.8	0.9	0.7	1.0	2.4 (0.3; 4.5)	2004-2022
						5.3 (3.8; 6.9)	2004-2012						6.7 (3.0; 10.5)	2004-2015	
						-2.0 (-3.1; -0.8)	2013-2022						-4.0 (-9.6; 1.8)	2016-2022	
II	N	130	137	119	111	103			59	72	74	52	65		
	CR	2.3	2.4	2.1	2.0	1.8			1.0	1.2	1.3	0.9	1.1		
	ESR2013	2.6	2.7	2.2	2.1	1.9	-3.1 (-3.7; -2.4)	2004-2022	0.9	1.1	1.2	0.8	1.0	0.1 (-1.3; 1.5)	2004-2022
						-0.7 (-2.1; 0.7)	2004-2014								
						-5.9 (-7.5; -4.2)	2015-2022								
III	N	325	298	310	329	306			98	94	97	112	93		
	CR	5.8	5.3	5.5	5.8	5.4			1.7	1.6	1.7	1.9	1.6		
	ESR2013	6.3	5.7	5.9	6.2	5.7	2.4 (1.5; 3.3)	2004-2022	1.6	1.6	1.6	1.8	1.5	2.4 (1.3; 3.5)	2004-2022
						6.9 (4.8; 9.1)	2004-2013						5.4 (2.9; 7.9)	2004-2013	
						-2.0 (-3.9; 0.0)	2014-2022						-0.5 (-2.8; 1.9)	2014-2022	
IV	N	435	488	453	479	444			110	124	108	111	132		
	CR	7.8	8.7	8.0	8.4	7.8			1.9	2.1	1.9	1.9	2.2		
	ESR2013	8.5	9.3	8.6	9.1	8.2	3.1 (2.0; 4.3)	2004-2022	1.8	2.1	1.7	1.8	2.1	4.1 (2.9; 5.3)	2004-2022
						-0.1 (-2.3; 2.1)	2004-2013						0.7 (-3.1; 4.7)	2004-2010	
						11.5 (6.5; 16.8)	2014-2017						5.9 (4.0; 7.7)	2011-2022	

Stage	Males							Females							
	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
						2.6 (-1.9; 7.4)	2018-2022								
X/NA	N	175	130	136	129	128		74	56	58	70	85			
	CR	3.1	2.3	2.4	2.3	2.2		1.3	1.0	1.0	1.2	1.4			
	ESR2013	3.6	2.6	2.7	2.5	2.4	-5.3 (-6.2; -4.4)	2004-2022	1.2	0.8	0.8	1.1	1.2	-3.8 (-4.9; -2.6)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Oesophageal cancer incidence trends: by tumour type

2.3.1. Oesophageal cancer incidence trends by type and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards

Type		Males							Females							
		2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
ADC	N	776	854	783	799	772			171	157	183	159	180			
	CR	13.9	15.2	13.8	14.1	13.5			3.0	2.7	3.1	2.7	3.1			
	ESR2013		15.3	16.6	15.1	15.2	14.4	1.1 (0.6; 1.5)	2004-2022	2.7	2.5	2.9	2.4	2.7	0.8 (0.1; 1.5)	2004-2022
								1.7 (1.0; 2.5)	2004-2015						1.9 (0.7; 3.0)	2004-2016
							0.1 (-1.2; 1.4)	2016-2022						-1.3 (-3.8; 1.2)	2017-2022	
SCC	N	388	311	332	341	306			196	209	179	200	212			
	CR	6.9	5.5	5.9	6.0	5.4			3.4	3.6	3.1	3.4	3.6			
	ESR2013	7.4	5.9	6.2	6.4	5.6	-1.2 (-1.8; -0.6)	2004-2022	3.3	3.5	2.9	3.3	3.4	0.9 (0.4; 1.4)	2004-2022	
Other and unspecified	N	72	51	58	64	74			38	26	28	31	44			
	CR	1.3	0.9	1.0	1.1	1.3			0.7	0.4	0.5	0.5	0.7			
	ESR2013	1.5	1.0	1.1	1.2	1.4	0.9 (0.0; 1.9)	2004-2022	0.6	0.4	0.4	0.5	0.7	1.2 (-0.5; 3.0)	2004-2022	
														-8.1 (-14.5; -1.2)	2004-2009	
														5.1 (2.6; 7.6)	2010-2022	

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.4. Oesophageal cancer incidence trends: by tumour sub-location

2.4.1. Oesophageal cancer incidence trends by sub-location and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards

Sub-location	Males							Females							
	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
Cervical	N	100	87	85	93	82									
	CR	1.8	1.5	1.5	1.6	1.4									
	ESR2013	1.9	1.7	1.6	1.7	1.5	3.4 (2.2; 4.6)	2004-2022	0.8	0.9	0.9	1.0	1.1	7.7 (6.1; 9.3)	2004-2022
						6.1 (3.6; 8.6)	2004-2014								
						0.1 (-2.9; 3.2)	2015-2022								
Thoracic	N	151	123	147	139	126									
	CR	2.7	2.2	2.6	2.4	2.2									
	ESR2013	2.9	2.3	2.7	2.6	2.3	4.1 (3.1; 5.1)	2004-2022	1.5	1.5	1.1	1.4	1.5	5.2 (4.0; 6.3)	2004-2022
						7.8 (5.1; 10.5)	2004-2012							7.3 (4.8; 9.9)	2004-2013
						1.3 (-0.7; 3.2)	2013-2022							3.1 (0.7; 5.5)	2014-2022
Abdominal	N	835	903	849	899	860									
	CR	14.9	16.0	15.0	15.8	15.1									
	ESR2013	16.4	17.4	16.3	17.1	16.0	3.0 (2.6; 3.5)	2004-2022	3.6	3.4	3.6	3.3	3.5	3.4 (2.7; 4.1)	2004-2022
						4.2 (3.4; 4.9)	2004-2015							4.9 (3.7; 6.2)	2004-2015
						1.3 (0.0; 2.6)	2016-2022							1.0 (-1.0; 3.0)	2016-2022
Unspecified	N	150	103	92	73	84									
	CR	2.7	1.8	1.6	1.3	1.5									
	ESR2013	2.9	2.0	1.8	1.4	1.6	-9.3 (-10.4; -8.2)	2004-2022	0.8	0.6	0.6	0.5	0.7	-8.6 (-10.0; -7.2)	2004-2022
						-2.4 (-7.2; 2.6)	2004-2009							-5.4 (-8.8; -1.9)	2004-2012
						-12.6 (-17.0; -7.9)	2010-2013							-12.7 (-18.4; -6.6)	2013-2016

Sub-location	Males							Females						
	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period
						-11.5 (-13.6; -9.4)	2014-2022						-10.0 (-14.6; -5.2)	2017-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

Note: The sub-location 'Abdominal' includes cardia (C16.0).

2.5. Oesophageal cancer incidence trends: by age group

2.5.1. Oesophageal cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period		
15-59	N	295	296	293	327	277	289	282	307	294	279	260	261	260	240	252	240	223	214	194			
	CR	9.2	9.2	9.1	10.1	8.5	8.8	8.6	9.3	8.9	8.4	7.8	7.8	7.8	7.2	7.6	7.2	6.7	6.4	5.8			
	ESR2013	9.9	9.7	9.5	10.5	8.8	9.1	8.8	9.5	9.0	8.4	7.8	7.7	7.6	7.0	7.4	7.0	6.4	6.2	5.7	-2.8 (-3.2; -2.5)	2004-2022	
																					-1.4 (-2.4; -0.5)	2004-2012	
																						-3.9 (-4.6; -3.2)	2013-2022
60-74	N	365	393	407	396	413	442	435	463	504	497	478	537	540	578	641	616	590	595	580			
	CR	53.6	57.4	59.2	56.6	58.0	60.8	58.7	61.2	65.5	63.4	60.0	66.1	64.9	67.5	72.9	68.6	64.3	63.7	61.3			
	ESR2013	53.5	57.1	59.2	56.9	58.7	61.1	59.7	62.6	65.9	64.8	60.5	66.9	65.5	68.5	74.0	69.3	65.2	64.5	62.3	1.0 (0.6; 1.5)	2004-2022	
																						1.9 (1.1; 2.7)	2004-2014
																						0.0 (-1.1; 1.0)	2015-2022
75+	N	190	205	237	252	226	259	270	319	253	296	332	301	317	343	343	360	360	395	378			
	CR	64.8	67.7	75.5	77.4	67.1	74.9	76.3	88.3	68.5	78.7	86.6	76.9	80.3	86.9	86.3	89.1	87.1	94.9	87.7			
	ESR2013	65.1	66.2	75.4	73.5	65.9	76.0	76.0	89.7	68.5	78.1	86.0	75.6	79.4	87.3	85.6	87.5	87.6	95.0	86.8	1.7 (1.1; 2.3)	2004-2022	

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.5.2. Oesophageal cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
15-59 N	59	68	66	75	61	69	67	85	83	71	56	65	73	65	64	62	51	63	64			
CR	1.9	2.2	2.1	2.4	1.9	2.1	2.1	2.6	2.5	2.2	1.7	2.0	2.2	2.0	1.9	1.9	1.6	1.9	1.9			
ESR2013	2.0	2.3	2.2	2.4	2.0	2.2	2.1	2.6	2.5	2.1	1.7	1.9	2.1	1.9	1.9	1.8	1.5	1.9	1.9	-1.4 (-2.4; -0.4)	2004-2022	
60-74 N	113	117	104	104	114	107	121	111	125	155	162	158	164	161	180	148	184	165	187			
CR	14.6	15.1	13.5	13.3	14.5	13.4	14.9	13.5	15.0	18.3	18.9	18.1	18.4	17.5	19.1	15.4	18.8	16.6	18.6			
ESR2013	14.1	15.0	13.4	13.3	14.4	13.6	15.1	13.5	15.1	18.4	19.2	18.2	18.4	17.9	19.3	15.5	18.9	16.7	18.7	1.6 (0.5; 2.7)	2004-2022	
																				2.1 (1.1; 3.1)	2004-2020	
																					-2.4 (-12.0; 8.4)	2021-2022
75+ N	121	125	107	133	117	129	136	152	151	146	170	154	159	143	161	182	155	162	185			
CR	23.3	23.5	19.7	23.9	20.5	22.3	23.2	25.6	25.2	24.2	27.9	25.0	25.8	23.3	26.3	29.6	25.0	26.2	29.2			
ESR2013	23.8	23.7	19.2	23.8	20.3	22.3	23.3	25.5	24.2	23.7	27.2	24.4	25.2	22.9	26.1	30.7	24.8	26.4	28.9	1.3 (0.6; 2.1)	2004-2022	

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3. CANCER PREVALENCE



3.1. Oesophageal cancer prevalence: by region

3.1.1. *Oesophageal cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022*

Region		Males				Females			
		1-year	5-year	10-year	15-year	1-year	5-year	10-year	15-year
Belgium	N	866	2,450	3,398	3,947	322	879	1,256	1,466
	CR	15.0	42.5	59.0	69	5.4	14.8	21.2	25
	ESR2013	15.7	44.4	61.8	72.0	5.1	13.9	19.7	22.9
Brussels	N	51	122	180	219	31	60	81	98
	CR	8.4	20.1	29.6	36.0	4.9	9.5	12.8	15.5
	ESR2013	12.5	30.4	45.9	56.9	6.2	12.0	16.0	19.6
Flanders	N	556	1,531	2,115	2,449	175	520	744	871
	CR	16.6	45.7	63.1	73.1	5.1	15.2	21.7	25.4
	ESR2013	16.3	44.7	61.9	71.7	4.5	13.5	19.3	22.5
Wallonia	N	259	797	1,103	1,279	116	299	431	497
	CR	14.4	44.3	61.2	71.0	6.2	15.9	22.9	26.4
	ESR2013	15.3	46.8	65.2	75.9	5.7	14.8	21.2	24.4



4.1. Oesophageal cancer survival: by region

4.1.1. *Oesophageal cancer survival by region, sex and age group: number at risk and net survival probabilities, 2013-2022*

Net Survival Probability, 2013-2022						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	All	15,305	57.5% (56.7%; 58.3%)	33.1% (32.3%; 33.9%)	27.0% (26.1%; 27.8%)	20.3% (18.8%; 22.0%)
Males						
Belgium	All ages	11,418	58.3% (57.3%; 59.2%)	32.6% (31.7%; 33.6%)	26.3% (25.4%; 27.4%)	19.8% (18.1%; 21.6%)
	15-59	2,402	67.4% (65.5%; 69.3%)	39.8% (37.8%; 41.9%)	31.6% (29.7%; 33.7%)	23.8% (21.5%; 26.4%)
	60-74	5,609	62.1% (60.9%; 63.5%)	35.4% (34.1%; 36.8%)	28.6% (27.2%; 30.0%)	21.1% (19.1%; 23.3%)
	75+	3,408	45.4% (43.6%; 47.2%)	22.8% (21.1%; 24.6%)	18.9% (17.0%; 21.0%)	14.6% (10.8%; 19.9%)
Brussels	All ages	699	56.7% (53.0%; 60.7%)	30.9% (27.4%; 35.0%)	23.2% (19.6%; 27.5%)	16.1% (11.8%; 22.1%)
	15-59	167	69.7% (63.0%; 77.1%)	36.9% (30.0%; 45.3%)	27.1% (20.6%; 35.7%)	20.9% (14.0%; 31.2%)
	60-74	329	57.4% (52.2%; 63.1%)	31.2% (26.3%; 37.0%)	25.3% (20.4%; 31.5%)	17.5% (11.5%; 26.6%)
	75+	203	45.0% (38.2%; 53.0%)	25.6% (19.3%; 34.0%)	16.7% (10.7%; 26.0%)	10.1% (3.9%; 26.1%)
Flanders	All ages	7,076	58.0% (56.8%; 59.2%)	32.6% (31.4%; 33.8%)	26.8% (25.5%; 28.1%)	20.8% (18.5%; 23.3%)
	15-59	1,418	67.5% (65.0%; 70.0%)	40.0% (37.5%; 42.8%)	31.2% (28.6%; 33.9%)	24.8% (21.8%; 28.3%)
	60-74	3,375	62.3% (60.7%; 64.1%)	36.0% (34.3%; 37.8%)	29.4% (27.6%; 31.3%)	21.9% (19.2%; 25.0%)
	75+	2,284	45.8% (43.6%; 48.0%)	22.8% (20.8%; 25.0%)	20.3% (18.0%; 22.9%)	16.7% (11.8%; 23.6%)
Wallonia	All ages	3,643	59.0% (57.4%; 60.7%)	33.0% (31.3%; 34.7%)	26.1% (24.4%; 27.9%)	18.7% (16.2%; 21.5%)

Net Survival Probability, 2013-2022							
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
	15-59	817	66.8% (63.7%; 70.2%)	40.0% (36.7%; 43.6%)	33.3% (30.0%; 36.9%)	22.6% (18.9%; 27.0%)	
	60-74	1,905	62.6% (60.4%; 64.9%)	35.1% (32.9%; 37.4%)	27.9% (25.6%; 30.3%)	20.5% (17.6%; 23.9%)	
	75+	921	44.5% (41.2%; 48.1%)	22.2% (19.2%; 25.8%)	15.9% (12.6%; 20.1%)	10.6% (5.7%; 19.7%)	
Females							
Belgium	All ages	3,887	55.2% (53.6%; 56.8%)	34.5% (32.9%; 36.2%)	28.8% (27.1%; 30.6%)	22.2% (19.1%; 25.9%)	
	15-59	629	73.2% (69.8%; 76.8%)	49.3% (45.4%; 53.5%)	40.7% (36.8%; 45.1%)	31.8% (27.3%; 37.1%)	
	60-74	1,653	61.9% (59.6%; 64.3%)	39.3% (36.9%; 41.8%)	32.8% (30.3%; 35.5%)	27.8% (24.5%; 31.5%)	
	75+	1,607	41.3% (38.8%; 43.9%)	23.8% (21.5%; 26.4%)	19.9% (17.3%; 22.8%)	12.8% (8.0%; 20.4%)	
Brussels	All ages	276	53.0% (47.3%; 59.4%)	29.9% (24.5%; 36.5%)	25.4% (19.9%; 32.4%)	10.7% (4.1%; 28.3%)	
	15-59	62	71.2% (60.8%; 83.3%)	56.4% (45.2%; 70.3%)	43.2% (31.7%; 58.8%)	33.0% (21.2%; 51.6%)	
	60-74	110	52.3% (43.7%; 62.6%)	23.7% (16.6%; 34.1%)	18.2% (11.5%; 28.9%)	FU<10y	
	75+	104	42.9% (34.0%; 54.1%)	21.0% (13.7%; 32.2%)	21.7% (13.4%; 35.0%)	FU<10y	
Flanders	All ages	2,258	55.7% (53.6%; 57.8%)	35.7% (33.5%; 37.9%)	29.6% (27.4%; 32.1%)	24.4% (20.4%; 29.2%)	
	15-59	356	75.8% (71.5%; 80.4%)	52.3% (47.3%; 58.0%)	44.1% (38.9%; 50.0%)	35.7% (29.3%; 43.4%)	
	60-74	891	64.1% (61.0%; 67.4%)	42.0% (38.7%; 45.6%)	35.5% (32.1%; 39.3%)	32.2% (27.7%; 37.5%)	
	75+	1,013	41.2% (38.1%; 44.5%)	24.2% (21.3%; 27.5%)	19.3% (16.2%; 23.1%)	13.9% (8.3%; 23.1%)	
Wallonia	All ages	1,353	54.9% (52.2%; 57.7%)	33.5% (30.8%; 36.4%)	28.0% (25.3%; 31.0%)	21.1% (16.5%; 27.0%)	
	15-59	211	69.4% (63.4%; 75.9%)	42.3% (36.0%; 49.7%)	34.3% (28.1%; 41.9%)	24.6% (18.2%; 33.3%)	
	60-74	652	60.5% (56.8%; 64.4%)	38.0% (34.3%; 42.1%)	31.4% (27.7%; 35.7%)	26.2% (21.6%; 31.8%)	
	75+	490	41.1% (36.8%; 46.0%)	23.7% (19.6%; 28.7%)	20.6% (16.2%; 26.2%)	13.2% (6.1%; 28.3%)	

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table.

4.2. Oesophageal cancer survival: by tumour stage

4.2.1. Oesophageal cancer survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022							
cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	15,305	57.5% (56.7%; 58.3%)	40.8% (40.0%; 41.6%)	33.1% (32.3%; 33.9%)	29.3% (28.4%; 30.1%)	27.0% (26.1%; 27.8%)	20.3% (18.8%; 22.0%)
Males							
All	11,418	58.3% (57.3%; 59.2%)	40.8% (39.8%; 41.7%)	32.6% (31.7%; 33.6%)	28.7% (27.7%; 29.7%)	26.3% (25.4%; 27.4%)	19.8% (18.1%; 21.6%)
I	1,125	83.8% (81.4%; 86.2%)	72.5% (69.6%; 75.5%)	65.3% (62.1%; 68.8%)	59.4% (55.9%; 63.1%)	55.3% (51.5%; 59.4%)	43.3% (37.1%; 50.5%)
II	1,384	71.9% (69.4%; 74.5%)	52.6% (49.8%; 55.5%)	42.9% (40.0%; 46.0%)	38.1% (35.2%; 41.3%)	35.0% (32.0%; 38.2%)	29.0% (24.7%; 34.0%)
III	3,010	67.4% (65.7%; 69.2%)	47.3% (45.4%; 49.2%)	37.8% (36.0%; 39.8%)	33.4% (31.5%; 35.4%)	30.7% (28.7%; 32.7%)	18.3% (15.2%; 21.9%)
IV	3,713	39.8% (38.2%; 41.4%)	19.9% (18.6%; 21.3%)	11.8% (10.7%; 13.0%)	8.8% (7.8%; 10.0%)	7.5% (6.5%; 8.7%)	6.7% (5.3%; 8.6%)
X/NA	2,240	55.6% (53.5%; 57.8%)	43.6% (41.5%; 45.9%)	37.1% (34.9%; 39.4%)	33.5% (31.2%; 35.9%)	31.2% (28.8%; 33.7%)	25.0% (20.6%; 30.2%)
Females							
All	3,887	55.2% (53.6%; 56.8%)	40.9% (39.3%; 42.6%)	34.5% (32.9%; 36.2%)	31.0% (29.3%; 32.7%)	28.8% (27.1%; 30.6%)	22.2% (19.1%; 25.9%)
I	410	75.1% (70.8%; 79.6%)	67.5% (62.7%; 72.7%)	61.3% (56.0%; 67.1%)	55.2% (49.5%; 61.6%)	50.0% (43.9%; 57.0%)	32.3% (20.4%; 51.1%)
II	616	64.6% (60.8%; 68.7%)	49.6% (45.6%; 54.0%)	43.1% (39.0%; 47.6%)	37.0% (32.8%; 41.7%)	33.7% (29.4%; 38.5%)	25.6% (18.4%; 35.6%)
III	925	65.0% (61.9%; 68.3%)	47.8% (44.5%; 51.3%)	40.0% (36.7%; 43.6%)	36.2% (32.9%; 39.9%)	33.6% (30.1%; 37.5%)	25.9% (20.1%; 33.4%)
IV	946	34.9% (32.0%; 38.2%)	18.2% (15.9%; 21.0%)	12.5% (10.4%; 14.9%)	10.2% (8.2%; 12.6%)	9.0% (7.0%; 11.5%)	6.3% (4.2%; 9.5%)
X/NA	1,004	51.8% (48.6%; 55.1%)	40.1% (36.9%; 43.5%)	34.2% (31.1%; 37.7%)	32.3% (29.0%; 35.9%)	31.2% (27.8%; 34.9%)	27.3% (21.6%; 34.6%)

4.2.2. Oesophageal cancer survival by pathological stage (pStage), and sex: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022							
pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	15,305	57.5% (56.7%; 58.3%)	40.8% (40.0%; 41.6%)	33.1% (32.3%; 33.9%)	29.3% (28.4%; 30.1%)	27.0% (26.1%; 27.8%)	20.3% (18.8%; 22.0%)
Males							
All	11,418	58.3% (57.3%; 59.2%)	40.8% (39.8%; 41.7%)	32.6% (31.7%; 33.6%)	28.7% (27.7%; 29.7%)	26.3% (25.4%; 27.4%)	19.8% (18.1%; 21.6%)
I	1,535	92.6% (91.0%; 94.1%)	86.7% (84.6%; 88.8%)	82.5% (80.0%; 85.0%)	78.7% (75.8%; 81.7%)	75.2% (72.0%; 78.6%)	63.3% (56.0%; 71.5%)
II	901	87.6% (85.3%; 90.0%)	74.0% (70.9%; 77.2%)	63.0% (59.5%; 66.8%)	57.9% (54.1%; 61.9%)	53.3% (49.3%; 57.7%)	33.2% (25.0%; 44.2%)
III	1,088	81.0% (78.5%; 83.5%)	57.6% (54.6%; 60.8%)	42.7% (39.6%; 46.1%)	35.8% (32.7%; 39.3%)	33.0% (29.8%; 36.5%)	25.3% (20.5%; 31.3%)
IV	700	49.4% (45.7%; 53.3%)	23.7% (20.7%; 27.2%)	12.8% (10.4%; 15.9%)	8.5% (6.4%; 11.4%)	6.2% (4.3%; 8.9%)	2.5% (0.8%; 7.9%)
X/NA	7,234	44.8% (43.7%; 46.0%)	26.1% (25.1%; 27.2%)	18.7% (17.7%; 19.7%)	15.4% (14.4%; 16.4%)	13.6% (12.7%; 14.6%)	9.4% (8.0%; 10.9%)
Females							
All	3,887	55.2% (53.6%; 56.8%)	40.9% (39.3%; 42.6%)	34.5% (32.9%; 36.2%)	31.0% (29.3%; 32.7%)	28.8% (27.1%; 30.6%)	22.2% (19.1%; 25.9%)
I	464	93.8% (91.3%; 96.4%)	89.9% (86.7%; 93.4%)	86.0% (82.0%; 90.1%)	83.2% (78.6%; 88.2%)	79.9% (74.6%; 85.6%)	73.8% (59.3%; 91.8%)
II	270	89.2% (85.3%; 93.3%)	74.4% (69.1%; 80.2%)	66.4% (60.4%; 72.9%)	58.6% (52.3%; 65.8%)	54.8% (48.1%; 62.4%)	43.1% (28.3%; 65.5%)
III	248	77.6% (72.4%; 83.3%)	59.1% (52.9%; 66.0%)	43.3% (37.0%; 50.8%)	37.5% (31.1%; 45.2%)	33.4% (26.9%; 41.6%)	25.2% (15.5%; 40.9%)
IV	176	50.7% (43.7%; 58.7%)	24.5% (18.8%; 31.9%)	13.5% (9.0%; 20.0%)	11.2% (7.1%; 17.7%)	8.3% (4.4%; 15.5%)	FU<10y
X/NA	2,738	43.6% (41.7%; 45.6%)	28.8% (27.1%; 30.7%)	23.2% (21.5%; 25.0%)	20.0% (18.3%; 21.8%)	18.3% (16.6%; 20.2%)	11.9% (9.3%; 15.3%)

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table.

4.2.3. Oesophageal cancer survival by stage and sex: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022							
Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	15,305	57.5% (56.7%; 58.3%)	40.8% (40.0%; 41.6%)	33.1% (32.3%; 33.9%)	29.3% (28.4%; 30.1%)	27.0% (26.1%; 27.8%)	20.3% (18.8%; 22.0%)
Males							
All	11,418	58.3% (57.3%; 59.2%)	40.8% (39.8%; 41.7%)	32.6% (31.7%; 33.6%)	28.7% (27.7%; 29.7%)	26.3% (25.4%; 27.4%)	19.8% (18.1%; 21.6%)
I	1,622	87.7% (85.9%; 89.5%)	79.7% (77.4%; 82.1%)	74.1% (71.4%; 76.8%)	68.6% (65.6%; 71.7%)	65.2% (62.0%; 68.7%)	53.3% (46.7%; 60.8%)
II	1,328	71.9% (69.4%; 74.6%)	53.5% (50.6%; 56.5%)	43.0% (40.0%; 46.1%)	38.6% (35.7%; 41.8%)	35.2% (32.2%; 38.6%)	25.4% (20.4%; 31.7%)
III	3,201	68.4% (66.7%; 70.1%)	48.1% (46.3%; 50.0%)	38.0% (36.2%; 39.9%)	33.4% (31.6%; 35.4%)	30.6% (28.7%; 32.6%)	19.8% (16.9%; 23.2%)
IV	3,826	39.9% (38.3%; 41.5%)	19.8% (18.5%; 21.1%)	11.6% (10.6%; 12.8%)	8.6% (7.6%; 9.7%)	7.2% (6.3%; 8.4%)	6.0% (4.5%; 7.9%)
X/NA	1,497	40.0% (37.5%; 42.6%)	25.8% (23.6%; 28.3%)	20.4% (18.2%; 22.8%)	17.3% (15.1%; 19.7%)	15.2% (13.0%; 17.7%)	12.7% (9.4%; 17.1%)
Females							
All	3,887	55.2% (53.6%; 56.8%)	40.9% (39.3%; 42.6%)	34.5% (32.9%; 36.2%)	31.0% (29.3%; 32.7%)	28.8% (27.1%; 30.6%)	22.2% (19.1%; 25.9%)
I	567	81.4% (78.0%; 84.9%)	76.2% (72.3%; 80.2%)	70.8% (66.5%; 75.4%)	66.3% (61.4%; 71.5%)	62.0% (56.7%; 67.7%)	49.6% (37.4%; 66.0%)
II	619	65.1% (61.3%; 69.2%)	50.2% (46.2%; 54.6%)	43.9% (39.8%; 48.4%)	37.7% (33.6%; 42.4%)	34.3% (30.1%; 39.1%)	25.7% (19.2%; 34.4%)
III	969	65.5% (62.5%; 68.7%)	48.4% (45.2%; 51.9%)	39.4% (36.2%; 43.0%)	35.3% (32.0%; 38.9%)	33.0% (29.6%; 36.7%)	25.1% (19.6%; 32.2%)
IV	980	34.6% (31.7%; 37.7%)	17.9% (15.6%; 20.6%)	12.1% (10.1%; 14.5%)	9.7% (7.8%; 12.1%)	8.2% (6.3%; 10.7%)	6.2% (4.1%; 9.2%)
X/NA	767	41.7% (38.3%; 45.6%)	27.8% (24.5%; 31.5%)	22.7% (19.5%; 26.4%)	21.2% (17.9%; 25.0%)	20.5% (17.2%; 24.5%)	15.4% (10.1%; 23.6%)

4.3. Oesophageal cancer survival: by tumour type and tumour stage

4.3.1. Oesophageal cancer survival by type, stage and sex: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022									
Type	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
Total		15,305	57.5% (56.7%; 58.3%)	40.8% (40.0%; 41.6%)	33.1% (32.3%; 33.9%)	29.3% (28.4%; 30.1%)	27.0% (26.1%; 27.8%)	20.3% (18.8%; 22.0%)	
Males									
Total	All	11,418	58.3% (57.3%; 59.2%)	40.8% (39.8%; 41.7%)	32.6% (31.7%; 33.6%)	28.7% (27.7%; 29.7%)	26.3% (25.4%; 27.4%)	19.8% (18.1%; 21.6%)	
	I	1,622	87.7% (85.9%; 89.5%)	79.7% (77.4%; 82.1%)	74.1% (71.4%; 76.8%)	68.6% (65.6%; 71.7%)	65.2% (62.0%; 68.7%)	53.3% (46.7%; 60.8%)	
	II	1,328	71.9% (69.4%; 74.6%)	53.5% (50.6%; 56.5%)	43.0% (40.0%; 46.1%)	38.6% (35.7%; 41.8%)	35.2% (32.2%; 38.6%)	25.4% (20.4%; 31.7%)	
	III	3,201	68.4% (66.7%; 70.1%)	48.1% (46.3%; 50.0%)	38.0% (36.2%; 39.9%)	33.4% (31.6%; 35.4%)	30.6% (28.7%; 32.6%)	19.8% (16.9%; 23.2%)	
	IV	3,826	39.9% (38.3%; 41.5%)	19.8% (18.5%; 21.1%)	11.6% (10.6%; 12.8%)	8.6% (7.6%; 9.7%)	7.2% (6.3%; 8.4%)	6.0% (4.5%; 7.9%)	
	X/NA	1,497	40.0% (37.5%; 42.6%)	25.8% (23.6%; 28.3%)	20.4% (18.2%; 22.8%)	17.3% (15.1%; 19.7%)	15.2% (13.0%; 17.7%)	12.7% (9.4%; 17.1%)	
ADC	All	7,533	61.4% (60.3%; 62.6%)	43.7% (42.5%; 44.9%)	34.9% (33.7%; 36.1%)	31.2% (30.0%; 32.5%)	29.2% (27.9%; 30.5%)	23.1% (20.9%; 25.7%)	
	I	1,189	90.4% (88.4%; 92.4%)	84.8% (82.2%; 87.4%)	80.9% (77.9%; 83.9%)	77.4% (73.9%; 81.0%)	74.5% (70.6%; 78.5%)	64.0% (55.3%; 74.2%)	
	II	688	77.2% (73.8%; 80.7%)	59.6% (55.7%; 63.9%)	47.8% (43.7%; 52.4%)	44.3% (40.0%; 49.0%)	41.8% (37.3%; 46.7%)	31.3% (23.7%; 41.2%)	
	III	2,157	71.6% (69.6%; 73.7%)	51.6% (49.4%; 53.9%)	40.5% (38.3%; 42.9%)	36.1% (33.8%; 38.6%)	34.1% (31.7%; 36.6%)	24.7% (20.8%; 29.4%)	
	IV	2,828	43.6% (41.7%; 45.5%)	22.1% (20.6%; 23.8%)	12.8% (11.5%; 14.2%)	9.3% (8.1%; 10.6%)	7.7% (6.6%; 9.1%)	7.0% (5.3%; 9.3%)	
	X/NA	673	36.4% (32.7%; 40.4%)	19.7% (16.7%; 23.3%)	13.8% (11.1%; 17.1%)	9.8% (7.4%; 12.9%)	7.4% (5.2%; 10.5%)	5.6% (3.5%; 9.1%)	
SCC	All	3,347	53.0% (51.3%; 54.8%)	35.6% (33.9%; 37.3%)	28.2% (26.6%; 29.9%)	23.3% (21.8%; 25.0%)	20.2% (18.6%; 21.9%)	12.6% (10.6%; 15.0%)	
	I	416	80.2% (76.2%; 84.3%)	65.6% (60.9%; 70.8%)	55.5% (50.4%; 61.1%)	44.0% (38.8%; 50.0%)	39.3% (34.0%; 45.5%)	26.3% (20.1%; 34.3%)	
	II	615	67.0% (63.2%; 71.0%)	47.2% (43.2%; 51.5%)	37.8% (33.8%; 42.3%)	32.2% (28.2%; 36.8%)	27.5% (23.5%; 32.2%)	18.8% (13.2%; 26.8%)	
	III	976	61.1% (58.0%; 64.3%)	40.7% (37.6%; 44.1%)	32.8% (29.8%; 36.1%)	27.7% (24.8%; 31.0%)	23.4% (20.5%; 26.8%)	11.1% (7.6%; 16.1%)	
	IV	892	30.3% (27.4%; 33.5%)	14.0% (11.9%; 16.6%)	8.9% (7.1%; 11.1%)	6.8% (5.2%; 8.9%)	5.8% (4.3%; 7.9%)	4.3% (2.4%; 7.7%)	
	X/NA	448	36.6% (32.3%; 41.4%)	23.6% (19.9%; 28.1%)	18.2% (14.7%; 22.5%)	15.5% (12.1%; 19.8%)	13.8% (10.4%; 18.4%)	10.6% (6.4%; 17.7%)	

Net Survival Probability, 2013-2022									
Type	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
Other and unspecified	All	596	49.1% (45.1%; 53.5%)	35.0% (31.1%; 39.3%)	29.8% (26.0%; 34.2%)	28.9% (24.9%; 33.4%)	27.3% (23.2%; 32.1%)	19.7% (13.1%; 29.8%)	
	I	18	N<50	N<50	N<50	N<50	N<50	N<50	
	II	25	N<50	N<50	N<50	N<50	N<50	N<50	
	III	70	72.1% (61.9%; 84.0%)	44.8% (34.2%; 58.8%)	32.9% (23.1%; 46.9%)	30.0% (20.3%; 44.2%)	25.1% (16.0%; 39.3%)	9.7% (3.4%; 28.1%)	
	IV	106	23.1% (16.3%; 32.7%)	5.2% (2.3%; 11.6%)	4.1% (1.6%; 10.4%)	4.3% (1.7%; 10.8%)	4.5% (1.8%; 11.4%)	FU<10y	
	X/NA	377	50.6% (45.6%; 56.1%)	39.8% (34.8%; 45.6%)	35.6% (30.5%; 41.5%)	34.4% (29.1%; 40.6%)	32.4% (26.8%; 39.3%)	30.2% (18.6%; 49.1%)	
Females									
Total	All	3,887	55.2% (53.6%; 56.8%)	40.9% (39.3%; 42.6%)	34.5% (32.9%; 36.2%)	31.0% (29.3%; 32.7%)	28.8% (27.1%; 30.6%)	22.2% (19.1%; 25.9%)	
	I	567	81.4% (78.0%; 84.9%)	76.2% (72.3%; 80.2%)	70.8% (66.5%; 75.4%)	66.3% (61.4%; 71.5%)	62.0% (56.7%; 67.7%)	49.6% (37.4%; 66.0%)	
	II	619	65.1% (61.3%; 69.2%)	50.2% (46.2%; 54.6%)	43.9% (39.8%; 48.4%)	37.7% (33.6%; 42.4%)	34.3% (30.1%; 39.1%)	25.7% (19.2%; 34.4%)	
	III	969	65.5% (62.5%; 68.7%)	48.4% (45.2%; 51.9%)	39.4% (36.2%; 43.0%)	35.3% (32.0%; 38.9%)	33.0% (29.6%; 36.7%)	25.1% (19.6%; 32.2%)	
	IV	980	34.6% (31.7%; 37.7%)	17.9% (15.6%; 20.6%)	12.1% (10.1%; 14.5%)	9.7% (7.8%; 12.1%)	8.2% (6.3%; 10.7%)	6.2% (4.1%; 9.2%)	
	X/NA	767	41.7% (38.3%; 45.6%)	27.8% (24.5%; 31.5%)	22.7% (19.5%; 26.4%)	21.2% (17.9%; 25.0%)	20.5% (17.2%; 24.5%)	15.4% (10.1%; 23.6%)	
ADC	All	1,713	56.5% (54.1%; 59.1%)	40.6% (38.2%; 43.2%)	32.8% (30.4%; 35.4%)	29.8% (27.4%; 32.5%)	27.8% (25.2%; 30.6%)	22.2% (17.4%; 28.4%)	
	I	258	89.7% (85.4%; 94.1%)	85.0% (79.8%; 90.6%)	79.6% (73.3%; 86.3%)	77.8% (70.7%; 85.5%)	74.6% (66.8%; 83.3%)	63.8% (44.3%; 92.0%)	
	II	185	65.3% (58.4%; 73.0%)	52.3% (45.0%; 60.7%)	45.5% (38.0%; 54.4%)	39.6% (32.1%; 49.0%)	38.1% (30.5%; 47.8%)	25.8% (15.5%; 43.1%)	
	III	480	68.4% (64.2%; 73.0%)	49.7% (45.1%; 54.7%)	38.1% (33.5%; 43.3%)	34.6% (29.9%; 40.0%)	31.0% (26.1%; 36.7%)	25.0% (16.6%; 37.6%)	
	IV	531	38.1% (34.2%; 42.6%)	18.6% (15.5%; 22.4%)	12.0% (9.4%; 15.4%)	8.9% (6.5%; 12.1%)	6.7% (4.4%; 10.2%)	FU<10y	
	X/NA	259	33.1% (27.5%; 39.8%)	16.4% (12.0%; 22.5%)	9.3% (5.9%; 14.7%)	7.8% (4.6%; 13.3%)	8.4% (4.9%; 14.3%)	7.7% (3.8%; 15.4%)	
SCC	All	1,888	54.2% (52.0%; 56.6%)	41.1% (38.8%; 43.5%)	35.6% (33.3%; 38.0%)	31.2% (29.0%; 33.7%)	28.6% (26.3%; 31.1%)	21.7% (18.2%; 25.7%)	
	I	294	74.8% (69.8%; 80.2%)	68.8% (63.3%; 74.7%)	63.1% (57.1%; 69.6%)	56.4% (50.0%; 63.6%)	51.3% (44.5%; 59.1%)	37.5% (26.2%; 53.8%)	
	II	420	65.3% (60.7%; 70.2%)	49.5% (44.7%; 54.8%)	44.0% (39.2%; 49.5%)	37.5% (32.6%; 43.1%)	32.9% (27.9%; 38.7%)	26.7% (19.7%; 36.2%)	
	III	471	62.2% (57.9%; 66.9%)	47.0% (42.5%; 51.9%)	40.5% (36.0%; 45.4%)	35.5% (31.1%; 40.6%)	34.2% (29.7%; 39.4%)	25.0% (18.9%; 33.0%)	
	IV	416	31.8% (27.5%; 36.6%)	18.3% (14.8%; 22.5%)	13.0% (9.9%; 16.9%)	11.4% (8.4%; 15.3%)	10.6% (7.7%; 14.6%)	8.7% (5.5%; 14.0%)	

Net Survival Probability, 2013-2022									
Type	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)	
	X/NA	288	36.8% (31.5%; 43.0%)	24.2% (19.6%; 30.0%)	20.0% (15.6%; 25.7%)	18.4% (14.0%; 24.1%)	16.2% (11.9%; 21.9%)	12.1% (7.5%; 19.4%)	
Other and unspecified	All	303	54.5% (49.1%; 60.6%)	42.7% (37.1%; 49.1%)	38.7% (33.0%; 45.4%)	36.3% (30.1%; 43.7%)	36.0% (29.6%; 43.8%)	27.6% (17.1%; 44.7%)	
	I	16	N<50	N<50	N<50	N<50	N<50	N<50	
	II	14	N<50	N<50	N<50	N<50	N<50	N<50	
	III	18	N<50	N<50	N<50	N<50	N<50	N<50	
	IV	33	N<50	N<50	N<50	N<50	N<50	N<50	
	X/NA	222	57.9% (51.5%; 65.0%)	45.6% (39.0%; 53.3%)	42.2% (35.3%; 50.3%)	40.9% (33.4%; 50.2%)	41.1% (33.1%; 51.0%)	31.8% (18.5%; 54.5%)	

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<kyears in the table.

5. CANCER SURVIVAL TRENDS



5.1. Oesophageal cancer survival trends: by tumour stage

5.1.1. Oesophageal cancer survival trends by stage and sex: number at risk and net survival probabilities, 2008-2022

Period	Stage	Males				Females			
		Net Survival Probability				Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2008-2012	All	5,011	55.9% (54.5%; 57.3%)	29.5% (28.1%; 30.8%)	23.3% (22.1%; 24.7%)	1,619	53.2% (50.7%; 55.7%)	30.9% (28.6%; 33.5%)	25.9% (23.6%; 28.5%)
	I	740	85.9% (83.2%; 88.8%)	71.2% (67.4%; 75.1%)	65.1% (60.9%; 69.6%)	230	85.6% (80.7%; 90.9%)	73.8% (67.2%; 81.0%)	67.1% (59.5%; 75.6%)
	II	738	70.0% (66.7%; 73.6%)	40.8% (37.2%; 44.8%)	33.2% (29.6%; 37.2%)	266	63.6% (57.8%; 69.9%)	39.2% (33.4%; 46.0%)	33.8% (28.1%; 40.8%)
	III	1,290	62.2% (59.6%; 65.0%)	29.3% (26.8%; 32.1%)	21.4% (19.1%; 24.0%)	356	62.6% (57.6%; 68.0%)	31.9% (27.2%; 37.4%)	25.0% (20.6%; 30.3%)
	IV	1,219	38.1% (35.4%; 41.0%)	8.6% (7.1%; 10.4%)	4.5% (3.5%; 6.0%)	313	34.2% (29.3%; 39.9%)	9.4% (6.6%; 13.4%)	5.7% (3.5%; 9.1%)
	X/NA	1,031	37.5% (34.5%; 40.7%)	16.3% (14.1%; 18.9%)	11.2% (9.2%; 13.6%)	455	36.5% (32.2%; 41.5%)	18.8% (15.2%; 23.3%)	15.5% (11.9%; 20.1%)
2013-2017	All	5,492	56.8% (55.5%; 58.2%)	31.3% (30.0%; 32.6%)	25.4% (24.1%; 26.7%)	1,889	53.7% (51.4%; 56.0%)	32.4% (30.2%; 34.7%)	26.4% (24.3%; 28.7%)
	I	807	86.7% (84.0%; 89.4%)	72.9% (69.2%; 76.7%)	63.3% (59.1%; 67.9%)	298	80.0% (75.3%; 85.0%)	67.7% (61.8%; 74.1%)	57.4% (50.9%; 64.8%)
	II	730	71.1% (67.7%; 74.7%)	41.6% (37.9%; 45.7%)	35.0% (31.2%; 39.2%)	297	65.7% (60.4%; 71.6%)	42.2% (36.6%; 48.6%)	33.4% (28.1%; 39.8%)
	III	1,638	66.1% (63.7%; 68.5%)	34.6% (32.3%; 37.2%)	27.8% (25.5%; 30.3%)	476	60.7% (56.4%; 65.4%)	35.4% (31.2%; 40.2%)	28.9% (24.8%; 33.7%)
	IV	1,528	34.0% (31.6%; 36.5%)	8.0% (6.7%; 9.5%)	5.1% (4.0%; 6.4%)	395	32.4% (28.0%; 37.4%)	10.3% (7.6%; 13.8%)	6.0% (4.0%; 9.0%)
	X/NA	803	38.6% (35.3%; 42.3%)	17.9% (15.1%; 21.1%)	12.3% (9.9%; 15.4%)	430	39.2% (34.6%; 44.3%)	18.1% (14.5%; 22.6%)	16.0% (12.5%; 20.5%)
2018-2022	All	5,937	59.6% (58.3%; 60.9%)	33.8% (32.4%; 35.2%)	27.2% (25.7%; 28.9%)	1,998	56.7% (54.4%; 59.0%)	36.7% (34.4%; 39.2%)	31.5% (28.8%; 34.6%)
	I	816	88.6% (86.2%; 91.2%)	75.1% (71.3%; 79.1%)	67.9% (62.8%; 73.6%)	269	83.0% (78.3%; 87.9%)	74.5% (68.4%; 81.2%)	70.2% (62.1%; 79.3%)
	II	598	73.0% (69.2%; 76.9%)	44.6% (40.1%; 49.6%)	34.2% (29.0%; 40.3%)	322	64.6% (59.3%; 70.3%)	45.8% (40.0%; 52.4%)	33.2% (26.3%; 42.0%)

Period	Stage	Males				Females			
		Net Survival Probability				Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	III	1,563	70.9% (68.5%; 73.3%)	41.8% (39.1%; 44.7%)	34.1% (31.0%; 37.5%)	493	70.2% (66.0%; 74.5%)	43.7% (39.0%; 49.0%)	37.8% (32.2%; 44.3%)
	IV	2,298	43.8% (41.8%; 45.9%)	14.2% (12.7%; 16.0%)	8.7% (7.2%; 10.5%)	585	36.0% (32.3%; 40.2%)	13.5% (10.7%; 16.9%)	9.8% (6.5%; 14.7%)
	X/NA	694	41.5% (37.9%; 45.5%)	23.6% (20.3%; 27.5%)	19.9% (16.2%; 24.5%)	337	45.0% (39.8%; 51.0%)	29.3% (24.0%; 35.7%)	28.6% (22.4%; 36.5%)

5.2. Oesophageal cancer survival trends: by tumour type and tumour stage

5.2.1. Oesophageal cancer survival trends by type, stage and sex: number at risk and net survival probabilities, 2008-2022

Type	Period	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
ADC	2008-2012	All	3,119	59.3% (57.5%; 61.1%)	32.0% (30.3%; 33.8%)	25.9% (24.2%; 27.7%)	694	56.6% (52.9%; 60.7%)	31.0% (27.4%; 35.0%)	26.2% (22.6%; 30.3%)
		I	560	87.8% (84.8%; 90.9%)	75.4% (71.2%; 79.9%)	69.5% (64.6%; 74.8%)	119	85.5% (78.5%; 93.1%)	72.2% (62.8%; 83.1%)	67.5% (56.7%; 80.3%)
		II	436	72.2% (67.9%; 76.8%)	42.0% (37.3%; 47.3%)	34.3% (29.6%; 39.7%)	100	71.5% (62.7%; 81.5%)	40.9% (31.5%; 52.9%)	32.3% (23.5%; 44.5%)
		III	778	67.5% (64.2%; 71.1%)	32.4% (29.1%; 36.2%)	23.7% (20.6%; 27.2%)	144	66.0% (58.5%; 74.6%)	31.3% (24.2%; 40.4%)	27.4% (20.5%; 36.6%)
		IV	808	39.9% (36.6%; 43.5%)	7.9% (6.2%; 10.1%)	4.0% (2.8%; 5.7%)	149	37.0% (29.9%; 45.7%)	10.8% (6.7%; 17.3%)	6.2% (3.3%; 11.9%)
		X/NA	537	36.4% (32.4%; 40.9%)	14.3% (11.4%; 18.0%)	9.7% (7.1%; 13.1%)	182	38.5% (31.7%; 46.8%)	15.2% (10.2%; 22.6%)	11.5% (6.8%; 19.3%)
	2013-2017	All	3,555	59.6% (57.9%; 61.3%)	33.2% (31.6%; 35.0%)	27.8% (26.1%; 29.6%)	867	54.7% (51.3%; 58.3%)	30.7% (27.5%; 34.2%)	25.7% (22.5%; 29.2%)
		I	585	88.5% (85.5%; 91.5%)	78.6% (74.4%; 83.0%)	71.0% (66.0%; 76.5%)	144	87.1% (81.0%; 93.6%)	76.8% (68.4%; 86.3%)	71.7% (62.0%; 82.9%)
		II	409	75.6% (71.3%; 80.3%)	45.6% (40.6%; 51.3%)	39.5% (34.3%; 45.5%)	109	64.9% (56.2%; 74.9%)	42.8% (33.9%; 54.0%)	36.4% (27.7%; 47.8%)
		III	1,058	69.4% (66.5%; 72.3%)	36.6% (33.6%; 39.8%)	30.5% (27.6%; 33.8%)	223	62.4% (56.2%; 69.4%)	33.6% (27.6%; 40.9%)	26.8% (21.0%; 34.1%)
		IV	1,088	37.1% (34.3%; 40.2%)	8.2% (6.7%; 10.1%)	5.1% (3.9%; 6.7%)	223	37.4% (31.4%; 44.4%)	9.5% (6.3%; 14.3%)	4.2% (2.2%; 8.0%)
		X/NA	415	37.0% (32.4%; 42.2%)	14.1% (10.7%; 18.6%)	7.8% (5.1%; 11.8%)	168	33.1% (26.4%; 41.6%)	7.9% (4.3%; 14.3%)	6.6% (3.2%; 13.3%)
	2018-2022	All	3,978	63.0% (61.5%; 64.6%)	36.4% (34.7%; 38.2%)	30.6% (28.7%; 32.7%)	846	58.5% (55.1%; 62.1%)	35.1% (31.6%; 39.1%)	29.9% (25.7%; 34.9%)
		I	604	92.3% (89.7%; 94.9%)	83.0% (78.8%; 87.3%)	78.9% (73.0%; 85.4%)	114	92.9% (87.5%; 98.7%)	83.3% (74.6%; 93.0%)	80.7% (68.9%; 94.5%)
		II	279	79.5% (74.3%; 84.9%)	51.2% (44.4%; 59.1%)	45.9% (38.1%; 55.3%)	76	65.9% (55.3%; 78.6%)	50.1% (37.9%; 66.0%)	39.4% (25.2%; 61.5%)
		III	1,099	73.8% (71.1%; 76.7%)	44.6% (41.3%; 48.2%)	38.0% (34.2%; 42.2%)	257	73.7% (68.1%; 79.7%)	42.3% (35.7%; 50.1%)	35.2% (27.3%; 45.4%)
		IV	1,740	47.6% (45.2%; 50.1%)	15.9% (14.0%; 18.0%)	9.6% (7.8%; 11.8%)	308	38.7% (33.5%; 44.7%)	14.0% (10.3%; 19.0%)	8.1% (4.2%; 15.7%)
		X/NA	258	35.5% (29.9%; 42.1%)	13.2% (9.4%; 18.7%)	7.4% (4.3%; 12.8%)	91	33.1% (24.2%; 45.3%)	12.7% (6.6%; 24.5%)	13.6% (7.1%; 26.3%)
SCC	2008-2012	All	1,658	51.4% (49.0%; 53.9%)	25.3% (23.2%; 27.5%)	18.5% (16.6%; 20.6%)	834	50.4% (47.0%; 54.0%)	30.6% (27.5%; 34.1%)	25.1% (22.1%; 28.5%)
		I	168	79.9% (73.7%; 86.5%)	56.9% (49.4%; 65.6%)	49.7% (42.0%; 58.9%)	103	85.5% (78.5%; 93.2%)	77.2% (68.2%; 87.3%)	67.5% (57.0%; 79.9%)

Type	Period	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		II	281	68.3% (62.9%; 74.1%)	39.9% (34.3%; 46.4%)	31.8% (26.4%; 38.2%)	159	60.1% (52.8%; 68.5%)	39.9% (32.7%; 48.8%)	36.3% (29.0%; 45.4%)
		III	465	54.4% (50.0%; 59.2%)	24.9% (21.1%; 29.4%)	17.7% (14.4%; 21.9%)	202	59.7% (53.2%; 67.0%)	32.9% (26.8%; 40.3%)	23.6% (18.2%; 30.6%)
		IV	347	38.1% (33.3%; 43.7%)	10.9% (8.0%; 14.8%)	5.6% (3.6%; 8.8%)	147	31.9% (25.1%; 40.5%)	8.5% (5.0%; 14.4%)	5.7% (3.0%; 11.1%)
		X/NA	397	35.4% (31.0%; 40.6%)	14.6% (11.4%; 18.6%)	8.2% (5.7%; 11.6%)	223	31.0% (25.4%; 37.9%)	15.0% (10.8%; 20.9%)	11.8% (8.0%; 17.5%)
	2013-2017	All	1,672	52.7% (50.3%; 55.2%)	27.8% (25.7%; 30.2%)	20.2% (18.2%; 22.4%)	895	52.7% (49.4%; 56.1%)	33.3% (30.3%; 36.7%)	25.9% (23.0%; 29.2%)
		I	210	82.1% (76.8%; 87.9%)	59.0% (52.3%; 66.7%)	43.0% (36.2%; 51.1%)	145	74.4% (67.4%; 82.1%)	59.0% (51.0%; 68.3%)	44.7% (36.5%; 54.8%)
		II	298	66.2% (60.9%; 72.0%)	36.6% (31.2%; 42.8%)	28.5% (23.3%; 34.7%)	175	66.4% (59.6%; 74.0%)	43.2% (36.2%; 51.7%)	32.3% (25.7%; 40.7%)
		III	531	59.4% (55.3%; 63.8%)	31.2% (27.4%; 35.6%)	22.7% (19.2%; 26.8%)	241	58.4% (52.4%; 65.1%)	36.6% (30.8%; 43.4%)	30.0% (24.5%; 36.7%)
		IV	358	26.8% (22.5%; 31.9%)	8.2% (5.8%; 11.7%)	5.5% (3.5%; 8.6%)	151	27.6% (21.3%; 35.7%)	12.2% (7.9%; 18.8%)	8.9% (5.3%; 15.0%)
		X/NA	275	36.6% (31.2%; 42.9%)	13.7% (10.1%; 18.7%)	8.3% (5.4%; 12.9%)	183	35.4% (29.0%; 43.3%)	16.8% (12.0%; 23.5%)	13.5% (9.1%; 19.9%)
	2018-2022	All	1,675	53.4% (51.0%; 55.9%)	28.6% (26.3%; 31.1%)	19.7% (17.1%; 22.6%)	993	55.7% (52.6%; 58.9%)	37.8% (34.6%; 41.3%)	32.0% (28.4%; 36.1%)
		I	206	78.1% (72.4%; 84.4%)	51.9% (44.6%; 60.6%)	34.4% (26.1%; 45.2%)	149	75.3% (68.4%; 82.9%)	67.2% (58.8%; 76.9%)	62.3% (51.9%; 74.8%)
		II	317	67.7% (62.5%; 73.3%)	39.1% (33.3%; 45.8%)	23.7% (17.4%; 32.2%)	245	64.5% (58.5%; 71.0%)	44.7% (38.3%; 52.1%)	31.8% (24.4%; 41.6%)
		III	445	63.1% (58.6%; 67.9%)	34.9% (30.2%; 40.2%)	24.0% (18.8%; 30.7%)	230	66.3% (60.3%; 72.9%)	45.0% (38.6%; 52.6%)	40.0% (32.8%; 48.7%)
		IV	534	32.6% (28.8%; 36.9%)	9.2% (6.9%; 12.4%)	5.7% (3.6%; 9.1%)	265	34.1% (28.9%; 40.4%)	13.5% (9.7%; 18.9%)	12.7% (8.8%; 18.3%)
		X/NA	173	36.5% (29.9%; 44.7%)	26.2% (19.8%; 34.6%)	26.9% (19.6%; 36.8%)	105	39.2% (30.7%; 50.0%)	26.0% (18.1%; 37.4%)	21.5% (13.2%; 34.9%)
Other and unspecified	2008-2012	All	243	43.8% (37.8%; 50.7%)	25.4% (20.3%; 31.9%)	24.6% (19.4%; 31.3%)	95	52.2% (42.7%; 63.7%)	35.3% (26.2%; 47.6%)	31.4% (21.9%; 45.1%)
		I	12	N<50	N<50	N<50	8	N<50	N<50	N<50
		II	21	N<50	N<50	N<50	7	N<50	N<50	N<50
		III	47	N<50	N<50	N<50	10	N<50	N<50	N<50
		IV	64	16.0% (9.2%; 27.8%)	5.0% (1.8%; 13.7%)	5.2% (1.9%; 14.3%)	17	N<50	N<50	N<50
		X/NA	99	51.9% (42.6%; 63.3%)	34.0% (25.3%; 45.5%)	31.9% (23.2%; 44.0%)	53	53.1% (40.8%; 69.2%)	49.1% (35.9%; 67.1%)	43.6% (29.3%; 64.9%)
	2013-2017	All	280	47.0% (41.4%; 53.5%)	28.0% (22.8%; 34.2%)	26.0% (20.8%; 32.6%)	136	54.8% (46.9%; 64.0%)	37.2% (29.6%; 46.9%)	33.9% (26.0%; 44.2%)

Type	Period	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		I	12	N<50	N<50	N<50	10	N<50	N<50	N<50
		II	23	N<50	N<50	N<50	13	N<50	N<50	N<50
		III	49	N<50	N<50	N<50	12	N<50	N<50	N<50
		IV	82	23.7% (16.1%; 34.9%)	3.0% (0.9%; 9.7%)	3.3% (1.0%; 10.8%)	21	N<50	N<50	N<50
		X/NA	114	50.4% (41.7%; 60.9%)	41.6% (32.8%; 52.9%)	38.9% (29.5%; 51.1%)	80	60.0% (49.9%; 72.0%)	42.6% (32.6%; 55.8%)	41.3% (30.7%; 55.6%)
	2018-2022	All	316	51.0% (45.6%; 57.0%)	31.3% (26.0%; 37.7%)	27.4% (21.0%; 35.7%)	167	54.3% (47.1%; 62.7%)	40.2% (32.3%; 50.1%)	39.9% (30.0%; 52.9%)
		I	6	N<50	N<50	N<50	6	N<50	N<50	N<50
		II	2	N<50	N<50	N<50	1	N<50	N<50	N<50
		III	21	N<50	N<50	N<50	6	N<50	N<50	N<50
		IV	24	N<50	N<50	N<50	12	N<50	N<50	N<50
		X/NA	263	50.7% (44.8%; 57.4%)	32.4% (26.5%; 39.7%)	28.4% (21.2%; 38.1%)	142	56.7% (48.9%; 65.8%)	42.2% (33.5%; 53.3%)	42.7% (31.5%; 58.0%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

6. CANCER MORTALITY



6.1. Oesophageal cancer mortality: by region

6.1.1. *Oesophageal cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021*

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Males																						
Belgium	0	0	0	0	1	1	1	0	5	14	16	44	77	85	108	86	65	46	18	3	570	11.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.3]	[0.3]	[0.0]	[1.3]	[3.7]	[4.0]	[10.9]	[21.2]	[27.7]	[40.7]	[49.4]	[49.7]	[59.2]	[64.1]	[55.0]	[10.0]	(10.0; 11.9)
Brussels	0	0	0	0	0	0	0	0	0	1	2	3	8	5	5	5	4	0	0	0	33	8.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.3]	[5.0]	[8.8]	[29.3]	[24.1]	[29.9]	[43.5]	[47.3]	[0.0]	[0.0]	[0.0]	[5.5]	(5.6; 11.6)
Flanders	0	0	0	0	1	0	1	0	4	10	11	30	53	50	71	62	48	38	13	2	394	12.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.0]	[0.5]	[0.0]	[1.9]	[4.7]	[4.7]	[12.3]	[24.0]	[26.6]	[43.8]	[54.3]	[55.6]	[73.5]	[70.9]	[55.9]	[12.0]	(10.9; 13.3)
Wallonia	0	0	0	0	0	1	0	0	1	3	3	11	16	30	32	19	13	8	5	1	143	9.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.0]	[0.0]	[0.9]	[2.4]	[2.4]	[8.8]	[13.9]	[30.7]	[37.0]	[39.2]	[36.2]	[38.2]	[66.0]	[71.1]	[8.0]	(7.6; 10.6)
Females																						
Belgium	0	0	0	0	0	1	0	0	0	2	4	8	23	33	24	35	20	20	8	8	186	2.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.0]	[0.0]	[0.0]	[0.5]	[1.0]	[2.0]	[6.2]	[10.1]	[8.1]	[16.4]	[10.8]	[14.8]	[12.1]	[41.6]	[3.2]	(2.5; 3.3)
Brussels	0	0	0	0	0	1	0	0	0	0	0	1	1	0	3	2	2	1	0	0	11	2.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.8]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[3.0]	[3.4]	[0.0]	[13.9]	[12.3]	[14.6]	[9.8]	[0.0]	[0.0]	[1.8]	(0.9; 3.5)

Region	N [CR]																				ESR2013 (95%CI)		
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages	
Flanders	0	0	0	0	0	0	0	0	0	2	2	4	9	24	15	23	17	14	7	1	118	3.1	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.0]	[0.9]	[1.7]	[4.1]	[12.4]	[8.6]	[17.3]	[14.6]	[16.5]	[17.5]	[8.9]	[3.5]	(2.5; 3.6)
Wallonia	0	0	0	0	0	0	0	0	0	0	2	3	13	9	6	10	1	5	1	7	57	2.8	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.6]	[2.4]	[10.7]	[8.3]	[6.0]	[15.7]	[1.8]	[12.5]	[4.9]	[115.9]	[3.1]	(2.1; 3.5)	

Note: Mortality, as registered with ICD-10 C15.

7. CANCER MORTALITY TRENDS



7.1. Oesophageal cancer mortality trends: by region

7.1.1. *Oesophageal cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period	
Belgium	N	487	464	460	499	515	495	540	497	514	589	563	554	586	539	560	605	565	570			
	CR	9.6	9.1	8.9	9.6	9.9	9.4	10.2	9.3	9.5	10.8	10.3	10.1	10.6	9.7	10.0	10.7	10.0	10.0			
	ESR2013	12.3	11.2	11.5	11.7	12.0	11.5	12.5	11.3	11.2	12.6	12.3	11.4	11.9	11.1	11.2	12.0	11.0	11.0	-0.3 (-0.7; 0.1)	2004-2021	
Brussels	N	34	39	33	33	33	36	46	35	26	29	44	35	23	31	19	43	34	33			
	CR	7.1	8.1	6.7	6.6	6.5	7.0	8.7	6.5	4.7	5.2	7.8	6.1	4.0	5.3	3.2	7.3	5.7	5.5			
	ESR2013	10.8	11.8	10.2	9.5	10.1	11.8	13.3	10.0	7.2	8.3	13.3	10.4	6.4	8.7	5.1	11.7	8.7	8.6	-2.0 (-4.2; 0.2)	2004-2021	
Flanders	N	294	255	281	301	324	302	333	303	324	377	354	343	378	343	365	402	364	394			
	CR	9.9	8.6	9.4	10.0	10.7	9.9	10.8	9.7	10.3	12.0	11.2	10.8	11.8	10.6	11.3	12.3	11.1	12.0			
	ESR2013	12.5	10.2	11.4	11.5	12.3	11.5	12.8	11.2	11.6	13.1	12.5	11.3	12.4	11.4	11.9	12.8	11.3	12.1	0.2 (-0.4; 0.9)	2004-2021	
Wallonia	N	159	170	146	165	158	157	161	159	164	183	165	176	185	165	176	160	167	143			
	CR	9.7	10.3	8.8	9.9	9.4	9.3	9.5	9.3	9.5	10.6	9.5	10.1	10.5	9.4	9.9	9.0	9.4	8.0			
	ESR2013	12.3	13.0	12.1	12.6	12.0	11.4	11.8	12.0	11.2	12.6	11.4	11.8	12.3	11.1	11.3	10.5	10.7	9.1	-1.7 (-2.3; -1.2)	2004-2021	
																				-0.7 (-1.2; -0.3)	2004-2019	
																					-8.7 (-13.1; -4.1)	2020-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

Note: Mortality, as registered with ICD-10 C15.

7.1.2. Oesophageal cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period			
Belgium	N	172	175	171	188	167	182	195	187	201	179	209	201	207	199	179	226	183	186					
	CR	3.2	3.3	3.2	3.5	3.1	3.3	3.5	3.4	3.6	3.2	3.7	3.5	3.6	3.5	3.1	3.9	3.1	3.2					
	ESR2013	3.4	3.3	3.2	3.4	3.0	3.3	3.4	3.4	3.2	3.4	2.9	3.4	3.4	3.2	3.3	2.8	3.6	2.8	2.9	-0.5 (-1.1; 0.2)	2004-2021		
Brussels	N	24	17	17	23	23	18	20	14	23	14	15	17	25	15	15	16	16	11					
	CR	4.6	3.2	3.2	4.3	4.2	3.3	3.6	2.4	3.9	2.4	2.5	2.8	4.1	2.5	2.5	2.6	2.6	1.8					
	ESR2013	5.0	3.7	3.6	4.7	4.7	3.6	4.3	2.7	4.0	2.5	3.1	3.6	5.1	2.8	2.7	3.3	3.0	2.2		-2.8 (-4.7; -0.9)	2004-2021		
Flanders	N	83	99	99	103	86	94	113	110	110	105	107	110	98	119	100	140	109	118					
	CR	2.7	3.2	3.2	3.3	2.8	3.0	3.6	3.4	3.4	3.3	3.3	3.4	3.0	3.6	3.0	4.2	3.3	3.5					
	ESR2013	2.8	3.2	3.2	3.1	2.7	2.9	3.3	3.2	3.1	2.9	2.9	3.0	2.5	3.2	2.6	3.7	2.7	3.1		-0.1 (-1.0; 0.8)	2004-2021		
Wallonia	N	65	59	55	62	58	70	62	63	68	60	87	74	84	65	64	70	58	57					
	CR	3.7	3.4	3.1	3.5	3.3	3.9	3.4	3.5	3.7	3.3	4.7	4.0	4.6	3.5	3.5	3.8	3.1	3.1					
	ESR2013	3.9	3.4	3.2	3.5	3.3	4.0	3.4	3.4	3.4	3.6	3.1	4.5	3.9	4.1	3.5	3.3	3.5	2.9	2.8		-1.2 (-2.3; -0.2)	2004-2021	
																						0.8 (-0.5; 2.1)	2004-2017	
																							-7.5 (-12.0; -2.7)	2018-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

Note: Mortality, as registered with ICD-10 C15.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021.

Mortality is reported by main group of ICD-10 classification.

Recommended reference: Cancer Fact Sheets 2022, Belgian Cancer Registry (BCR), 2025